Spatial Biology for Drug Development Summit on October 22-23, 2025 in Boston, United States

As spatial biology technology advances, delivering unprecedented resolution, multiplexing, and reproducibility, new insights into disease biology are driving major breakthroughs across multiple therapeutic areas. Yet, key barriers still limit the full application of spatial biology in drug development. Overcoming these challenges is critical to achieving widespread adoption in research settings and beyond.

The 3rd Spatial Biology for Drug Development Summit is your opportunity to come together with leading biopharma experts to address these hurdles head-on. Across an intensive 2-day agenda, you’ll explore practical solutions to issues spanning data infrastructure, multi-omics integration, standardization, scalability, and translation into the clinic. This year’s forum will equip you with the latest data-driven strategies to not only overcome obstacles but to maximize the value of spatial biology for deeper disease insights, robust target identification, biomarker discovery, and more.

URLs:

Tickets: https://go.evvnt.com/3165742-2?pid=10008

Brochure: https://go.evvnt.com/3165742-3?pid=10008

Time: 7:00 AM - 5:00 PM

Prices:

Solution and Service Provider - Conference Pass: USD 3699.00,

Free to Attend* for Drug Developers and Academics** - Conference Pass: USD 0.50

Speakers: Alexander Klimowicz Principal Scientist Senior Research Fellow and Head of Spatial Biology - Immunology and Respiratory Discovery Boehringer Ingelheim, Alyssa Schwartz Director - Biology Immunome Inc., Andrey Tovchigrechko Director - Bioinformatics and Sequencing BioNTech, Chandra Saravanan Director, Pathology Novartis, Chi Ngai Chan Director, Tissue Technologies Unit Beth Israel Deaconess Medical Center, Deidre Dalmas Director - Investigative Safety CPATH-PSTC, Emre Arslan Associate Director Takeda, Fei Wang Postdoctoral fellow AbbVie, Guneet Walia Senior Director, Data Science and Digital Health Johnson and Johnson, Kai-Chih Huang Senior Computational Scientist Pfizer, Michael Surace Director, Translational Medicine, Cancer Biomarker Discovery AstraZeneca, Rouba Kozak Director - Mental Health, Neuroscience FNIH, Subba Chintalacharuvu Executive Director - Translational Immunology Genentech, Sunish Mohanan Senior Director - Research Pathology Gilead, Tim Holzer Executive Director, Clinical Diagnostics Laboratory Eli Lilly, Vanessa M. King Director - Companion Diagnostics Daiichi Sankyo, Vipul Baxi Executive Director, Computational Imaging and Digital Biomarkers Amgen, William Hwang Assistant Professor - Principal Investigator Massachusetts General Hospital, Harvard Medical School, Ying Zhang Head - Next Generation Sequencing, Systems and Immunology Group Pfizer, Yu Tian Director II, Research Development Digital and Data Strategy AbbVie